Benefits and risks of ovarian function and reproduction for cancer development and prevention

被引:6
|
作者
Schindler, Adolf E. [1 ]
机构
[1] Inst Med Res & Educ, D-45122 Essen, Germany
关键词
Ovarian function; pregnancy; progesterone; progestogens; ovarian cancer; breast cancer; endometrial cancer; SEX-STEROID-HORMONES; LIFE-STYLE FACTORS; BREAST-CANCER; ORAL-CONTRACEPTIVES; ENDOMETRIAL CANCER; PREGNANCY; OVULATION; WOMEN; INFERTILITY; PROTECTION;
D O I
10.3109/09513590.2011.569788
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ovarian function and menstrual cycle disturbances, pregnancy, and reproductive medicine procedures can either increase gynecological cancer risk or prevent cancer development. For ovarian cancer development, there are two hypotheses, which are connected with ovulation and gonadotropin secretion. Most of the ovarian cancers seem to be derived from displaced ovarian surfice epithelial cells. One year of ovulatory cycles increases the ovarian cancer risk by 6%. Ovulation between 22 and 29 years of age causes the highest risk increase per year. In contrast, progesterone or progestins appear to create protection. Lifestyle can affect or modify ovarian cancer risk. Breast cancer risk is very much related to age of menarche and menopause, pregnancy, and breast feeding. All of which are related to ovarian function and progestogenic impact that translates either into breast cancer risk increase or decrease. This is modified by body mass index, physical activity, and lifestyle in general. The risk of endometrial cancer is most closely related to endogenous progesterone during the menstrual cycle and pregnancy or by exogenous progestogens as in oral contraceptives. These effects are progestogen dose and time dependent. Endometrial cancer risk can also be increased by estrogen-producing tumors or long-term estrogen treatment.
引用
收藏
页码:1043 / 1047
页数:5
相关论文
共 50 条
  • [31] RISKS AND BENEFITS OF CANCER CHEMOTHERAPY
    SCHMAHL, D
    GEBURTSHILFE UND FRAUENHEILKUNDE, 1976, 36 (03) : 210 - 212
  • [32] The benefits and risks of PrEP and kidney function
    Mocroft, Amanda
    Ryom, Lene
    Lancet HIV, 2016, 3 (11): : E501 - E502
  • [33] Prevention of ovarian cancer
    Hanna, L
    Adams, M
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2006, 20 (02) : 339 - 362
  • [34] Prevention of ovarian cancer
    Brewer, MA
    Mitchell, MF
    Bast, RC
    IN VIVO, 1999, 13 (01): : 99 - 106
  • [35] Risks and benefits of screening asymptomatic women for ovarian cancer: A systematic review and meta-analysis
    Reade, Clare J.
    Riva, John J.
    Busse, Jason W.
    Goldsmith, Charlie H.
    Elit, Laurie
    GYNECOLOGIC ONCOLOGY, 2013, 130 (03) : 674 - 681
  • [36] CANCER RISKS AND CANCER PREVENTION IN SWEDEN
    WENNSTROM, G
    MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1987, 4 (3-4): : 273 - 276
  • [37] RISKS VS BENEFITS IN DRUG DEVELOPMENT
    BALLARD, RW
    FOOD DRUG COSMETIC LAW JOURNAL, 1968, 23 (01): : 25 - 28
  • [38] Systemic benefits of cyclic ovarian function
    Berga, SL
    JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2001, 8 (01) : S3 - S6
  • [39] Systemic Benefits of Cyclic Ovarian Function
    Sarah L. Berga
    The Journal of the Society for Gynecologic Investigation: JSGI, 2001, 8 (Suppl 1): : S3 - S6
  • [40] From hazard identification to weighing the risks and benefits of prevention
    Vainio, H
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2004, 197 (03) : 165 - 165